Publications

Peer-Reviewed Publications

2022

• Chilamakuri R, Rouse DC, Agarwal S* (2022) Inhibition of Polo-like Kinase 1 by HMN-214 Blocks Cell Cycle Progression and Inhibits Neuroblastoma Growth. Pharmaceuticals, 15(5), 523; Doi: 10.3390/ph15050523. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144399/

• Chilamakuri R, Agarwal S* (2022) Dual targeting of PI3K and HDAC by CUDC-907 inhibits pediatric neuroblastoma growth. Cancers 14(4), 1067; DOI:10.3390/cancers14041067; PMID: 35205815; PMCID: PMC8870466. www.ncbi.nlm.nih.gov/pmc/articles/PMC8870466/

• Chilamakuri R, Rouse DC, Yang Yu, Kabir A, Muth A, Jang Y, Lipton JM, Agarwal S* (2022) BX-795 inhibits neuroblastoma growth and enhances sensitivity towards Chemotherapy. Translational Oncology, 15(1): 101272. DOI: 10.1016/j.tranon.2021.101272; PMID: 34823094. www.ncbi.nlm.nih.gov/pmc/articles/PMC8626612/

• Parvathaneni V, Chilamakuri R, Kulkarni NS, Wang X, Agarwal S, Gupta V* (2022). Repurposing Clofazimine for Malignant Pleural Mesothelioma Treatment – In-vitro Assessment of Efficacy and Mechanism of Action. Life Sciences. pubmed.ncbi.nlm.nih.gov/35908620/

2021

• Chilamakuri R , Agarwal S*. (2021) COVID-19: Characteristics and Therapeutics. Cells 21;10(2):206. doi: 10.3390/cells10020206. PMID: 33494237; PMCID: PMC7909801. www.ncbi.nlm.nih.gov/pmc/articles/PMC7909801/

Abstracts

2022

• Direct targeting of epigenetic regulator Menin inhibits neuroblastoma growth. Chilamakuri R, Agarwal S*. In American Society for Pharmacology and Experimental Therapeutics April 2022, International Conference. Nominated for Student Post-doc Poster Awards.

• Inhibition of PLK-1 by using a Small Molecule Inhibitor HMN-214 is a Novel Therapeutic Approach for High-risk Neuroblastoma. Chilamakuri R, Agarwal S*. In American Society for Biochemistry and Molecular Biology April 2022, International Conference.

• Inhibition of Epigenetic Regulator Menin is a Novel Therapeutic Approach for High-risk Neuroblastoma. Chilamakuri R, Agarwal S*. In AACR Annual Meeting. April 2022, International Conference.

• Inhibition of CXCR2 Inhibits Neuroblastoma Growth and Progression. Alkhamisy J, Chilamakuri R , Foroutan N, Rouse DC, Agarwal S*. In SJU Research Month 2022. Local Conference

• Inhibition of PLK1 Induces Mitotic Cell Death and Inhibits Growth in Pediatric Neuroblastoma. Foroutan N , Chilamakuri R, Rouse DC , Agarwal S*. In SJU Research Month 2022. Local Conference.

• Direct Targeting of c-MET is a Novel Therapeutic Approach for High-Risk Neuroblastoma. Lee J, Chilamakuri R , Rouse DC , Foroutan N, Agarwal S*. In SJU Research Month 2022. Local Conference.

• Targeting the WEE1 Kinase as a Molecular Targeted Therapy for Neuroblastoma. Rouse DC, Chilamakuri R , Foroutan N , Agarwal S*. In SJU Research Month 2022. Local Conference.

• Direct Inhibition of Survivin using YM-155 Inhibits Neuroblastoma Progression. Danielle Rouse, Rameswari Chilamakuri, and Saurabh Agarwal*. In SJU Research Month 2022. Oral Presentation.

2021

• Chilamakuri R, Sharma B, Rouse DC, Agarwal S*. Direct targeting of MAPK/ERK signaling pathway is a novel therapeutic approach for high-risk neuroblastoma. In AACR Annual Meeting. May 2021, International.

• Rouse DC, Chilamakuri R, Agarwal S* "Targeting of Survivin Inhibits Neuroblastoma Cell Proliferation.” In American Society for Biochemistry and Molecular Biology (ASBMB) Annual Meeting. April 2021, International Conference.

• Chilamakuri R , Sharma B, Rouse DC, Agarwal S “Novel Dual PI3K and PLK1 Inhibitor Inhibits NB Growth.” In SJU Research Month 2021. Local Conference.

• Chilamakuri R, Sharma B , Rouse DC, Agarwal S “Inhibition of MEK Pathway Inhibit High-Risk Neuroblastoma Proliferation.” In SJU Research Month 2021. Local Conference.

• Chilamakuri R, Sharma B, Rouse DC, Agarwal S “Direct Targeting of BRD4 by a Novel PROTAC Nanoparticle Inhibits High-Risk Neuroblastoma Growth.” In SJU Research Month 2021. Local Conference.

• Chilamakuri R, Sharma B, Rouse DC, Agarwal S “Inhibition of PI3K Pathway Inhibits Neuroblastoma Growth.” In SJU Research Month 2021. Local Conference.

• Chilamakuri R, Sharma B , Rouse DC, Agarwal S “Dual Targeting of PI3K and HDAC Inhibits Oncogenic Potential of NB.” In SJU Research Month 2021. Local Conference.

• Chilamakuri R , Sharma B , Rouse DC , Agarwal S “Direct Targeting of CXCR2 is Novel Therapeutic Approach for High-Risk Neuroblastoma.” In SJU Research Month 2021. Local Conference.

• Chilamakuri R, Sharma B, Rouse DC, Agarwal S “Small Molecule PDK1 Inhibitor Inhibits Neuroblastoma Growth and Enhances Sensitivity Towards Chemotherapy.” In SJU Research Month 2021. Local Conference.

• Rouse DC, Chilamakuri R, Sharma B, Agarwal S “Targeting of Survivin Inhibits Neuroblastoma Cell Proliferation.” In SJU Research Month 2021. Local Conference.

2020

• Chilamakuri R, Agarwal S “Targeting of AKT pathway inhibit high-risk neuroblastoma growth.” In AACR Annual Meeting. May 2020, International.

• Chilamakuri R, Agarwal S “Development of Novel Therapeutic Strategy for Pediatric Neuroblastoma by Targeting PI3K Signaling Pathway.” In AAPS PharmSci 360 2020. International Conference.

• Chilamakuri R , Agarwal S “Characterizing and Targeting Epigenetic regulators in Neuroblastoma Cancer Stem Cells.” In AAPS PharmSci 360 2020. International Conference.

• Chilamakuri R, Agarwal S “Targeting of AKT pathway inhibit high-risk neuroblastoma growth.” In AAPS PharmSci 360 2020. International Conference.

• Chilamakuri R, Agarwal S “Inhibition of cancer cell signaling pathways inhibit pediatric neuroblastoma growth.” In AAPS PharmSci 360 2020. International Conference.

• Saraswat A , Chilamakuri R, Agarwal S, Patel K (SJU) “Nanoformulation development of a novel BRD4 PROteolysis-TArgeting Chimeric (PROTAC) to target N-Myc oncogene in neuroblastoma” In AAPS PharmSci 360 2020. International Conference.

• Chilamakuri R, Sharma B, Agarwal S “Targeting the Cell Cycle Checkpoints is a Novel Therapeutic Approach for Neuroblastoma.” In AAPS PharmSci 360 2020. International Conference.

• Chilamakuri R, Patki M, Patel K, Agarwal S “Direct Targeting of BRD4 by Novel PROTAC Nanoparticles Inhibit High-risk Neuroblastoma Growth.” In AAPS PharmSci 360 2020. International Conference. Best Poster Abstract Award Winner

• Chilamakuri R, Kantamneni S, Rouse DC, Lopez GR, Agarwal S “Targeting of AKT Pathway Inhibit High-Risk Neuroblastoma Growth.” In SJU Research Month 2020. Local Conference.

• Lopez GR, Chilamakuri R, Agarwal S “Development of Novel Therapeutic Strategy for Pediatric Neuroblastoma by Targeting PI3K Signaling Pathway.” In SJU Research Month 2020. Local Conference.

• Rouse DC, Kantamneni S, Chilamakuri R, Lopez GR, Agarwal S “Inhibition of Cancer Cell Signaling Pathways Inhibit Pediatric Neuroblastoma Growth.” In SJU Research Month 2020. Local Conference.

• Sharma B, Chilamakuri R, Agarwal S “Targeting the Cell Cycle Checkpoints is a Novel Therapeutic Approach for Neuroblastoma.” In SJU Research Month 2020. Local Conference.

2019

• Chilamakuri R, Sharma B, Kim HM, Agarwal S* “Targeting PDK1 and PI3K Inhibit Proliferation of High-Risk Neuroblastoma Cells”, in AAPS PharmiSci360, November 2019, San Antonio, USA, International.